Hexarelin

Research protocols typically use 200-300 mcg/day, divided into 100 mcg doses 2-3 times daily via subcutaneous injection. Starting dose of 100 mcg/day recommended for tolerance assessment. Cycles of 12-16 weeks followed by mandatory 4-6 week breaks to prevent receptor desensitization. Partial tolerance develops with prolonged use (50-75% efficacy decrease over weeks to months). Hexarelin reached Phase II clinical trials but was never marketed. Note: Hexarelin and Examorelin are the same compound (INN: Examorelin).

Binds to growth hormone secretagogue receptors (GHS-R1a) on pituitary somatotroph cells, activating intracellular signaling via calcium mobilization, protein kinase C activation, and phospholipase C / IP3 production.

Interacts with hypothalamic neurons to potentiate endogenous GHRH signaling, amplifying GH pulses beyond what direct pituitary stimulation alone achieves.

Functionally antagonizes somatostatin-mediated inhibition of GH release, permitting larger amplitude GH secretory pulses.

Uniquely among GHRPs, hexarelin demonstrates direct cardioprotective effects through the CD36 scavenger receptor, independent of GH release. Activates endothelial nitric oxide synthase and improves cardiac contractility.

One of the most potent synthetic GH secretagogues, producing significant IGF-1 elevation (up to 220% above baseline) and robust pulsatile GH output.

Promotes lean muscle mass through GH/IGF-1-mediated protein synthesis, nitrogen retention, and anabolic signaling.

Supports fat metabolism and body recomposition through GH-mediated lipolysis.

Reduced infarct size by 25-40% in ischemia-reperfusion animal models. Cardioprotective effects operate independently of GH release through CD36 receptor pathway.

Enhanced tendon and ligament strength, improved flexibility and joint health, faster recovery from injuries and training.

GH release patterns associated with improved deep sleep quality and energy levels.

GH-releasing peptide-2 (GHRP2) can be used for provocative growth hormone testing (GHT). Since it ac...

Journal of pediatric endocrinology & metabolism : JPEM · Takanori Onuki, Tadokoro Hiroaki, Kentaro Sawano, Nao Shibat...

Growth Hormone-Releasing Peptide 6 (GHRP-6) (His-(D-Trp)-Ala-Trp-(D-Phe)-Lys-NH2) is an agonist of t...

Fish & shellfish immunology · Liz Hernández, Hanlet Camacho, Adriana Nuñez-Robainas, Danie...

Ghrelin, a growth hormone-releasing peptide that was first discovered in the stomach of rats in 1999...

Peptides · Takeshi Tokudome, Kentaro Otani, Mikiya Miyazato, Kenji Kang...

Growth hormone (GH) increases lean body mass, decreases fat mass, increases exercise tolerance and m...

Sexual medicine reviews · John T Sigalos, Alexander W Pastuszak

Growth hormone secretagogues (GHSs) possess the ability to release growth hormone (GH) in the body. ...

Yonsei medical journal · Junghun Lee, Ahreum Kwon, Hyun Wook Chae, Woo Jung Lee, Tae ...